Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design

The phosphatidylinositol 3-kinase (PI3K) signaling pathway plays crucial roles in cell growth, proliferation and survival Genomic aberrations in the PI3K pathway, such as mutational activation of PI3K alpha or loss of function of tumor suppressor PTEN, have been closely linked to the development and progression of a wide range of cancers Hence, inhibition of the key targets in the pathway, e g PI3K, AKT, mTOR, offers great potential for the treatment of cancer Lead optimization through integration of structure based drug design (SBDD) and physical properties-based optimization (PPBO) led to the discovery of 2-amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one (PF-04691502, 1) that demonstrated potent in vitro inhibitory activity against both PI3K and mTOR, excellent kinase selectivity, good ADMET, and robust in vivo efficacy in a mouse xenograft tumor growth model Compound 1 is currently being evaluated in human clinical trials for the treatment of cancer